• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CARL ZEISS MEDITEC CATARACT TECHNOLOGY INC. MICOR LENS FRAGMENTATION SYSTEM; PHACOFRAGMENTATION SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CARL ZEISS MEDITEC CATARACT TECHNOLOGY INC. MICOR LENS FRAGMENTATION SYSTEM; PHACOFRAGMENTATION SYSTEM Back to Search Results
Model Number FG-50621
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Vitreous Loss (2142); Capsular Bag Tear (2639)
Event Date 06/14/2023
Event Type  Injury  
Event Description
A 71-year-old female patient underwent cataract surgery in the left eye on (b)(6) 2023 where the micor lens fragmentation system (extractor and drive) was used to remove the cataractous lens fragments.During the micor procedure there was anterior chamber fluctuation and the posterior capsule tore which resulted in vitreous fluid loss.A vitrectomy was performed and a 3-piece intraocular lens was implanted in the sulcus.Preoperatively, the patient's best corrected visual acuity (bcva) was 20/25.Postoperatively, the patient's bcva improved to 20/20 and the patient was reported as doing well.
 
Manufacturer Narrative
The micor extractor was returned to the manufacturer and evaluated.The device was subjected to visual inspection, functional testing, then disassembled for internal inspection.There was no damage or device malfunction identified and the device met specifications and performed as intended.The published literature was reviewed for comparison of the functional test results for forced occlusion response; the investigation data shows the device operates within the same expected ranges for similar marketed phacoemulsification devices.The micor extractor device history records were reviewed for this manufacturing lot and there were no discrepancies or unusual findings that relate to the reported event.Based on the information reviewed, there is no evidence to indicate the presence of a potential quality issue with respect to manufacturing, design, or labeling.The device labeling identifies capsular rupture as an inherent safety risk.Manufacturer's reference #:(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
MICOR LENS FRAGMENTATION SYSTEM
Type of Device
PHACOFRAGMENTATION SYSTEM
Manufacturer (Section D)
CARL ZEISS MEDITEC CATARACT TECHNOLOGY INC.
8740 technology way
reno NV 89521
Manufacturer (Section G)
CARL ZEISS MEDITEC CATARACT TECHNOLOGY, INC.
8740 technology way
reno NV 89521
Manufacturer Contact
andrew rybold
8740 technology way
reno 89521
7754731014
MDR Report Key17329610
MDR Text Key319182083
Report Number3012123033-2023-00003
Device Sequence Number1
Product Code HQC
UDI-Device Identifier00860000122368
UDI-Public00860000122368
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K222236
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 07/14/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date11/15/2023
Device Model NumberFG-50621
Device Lot NumberFG23051801
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer06/30/2023
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 06/14/2023
Initial Date FDA Received07/14/2023
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured05/19/2023
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age71 YR
Patient SexFemale
Patient EthnicityNon Hispanic
Patient RaceBlack Or African American
-
-